27. Hepatitis B: Prognosis and Treatment

  1. John WD McDonald Professor of Medicine2,
  2. Andrew K Burroughs Professor of Hepatology Consultant Physician/Hepatologist3,
  3. Brian G Feagan Professor of Medicine2 and
  4. M Brian Fennerty Professor of Medicine4
  1. Piero Luigi Almasio,
  2. Calogero Cammà,
  3. Vito Di Marco and
  4. Antonio Craxì

Published Online: 22 JUL 2010

DOI: 10.1002/9781444314403.ch27

Evidence-Based Gastroenterology and Hepatology, Third Edition

Evidence-Based Gastroenterology and Hepatology, Third Edition

How to Cite

Almasio, P. L., Cammà, C., Di Marco, V. and Craxì, A. (2010) Hepatitis B: Prognosis and Treatment, in Evidence-Based Gastroenterology and Hepatology, Third Edition (eds J. W. McDonald, A. K. Burroughs, B. G. Feagan and M. B. Fennerty), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444314403.ch27

Editor Information

  1. 2

    Robarts Clinical Trials, Robarts Research Unit, University of Western Ontario, London, Ontario, Canada

  2. 3

    The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, and University College London, London, UK

  3. 4

    Oregon Health and Science University, Division of Gastroenterology and Hepatology, Portland, Oregon, USA

Author Information

  1. Division of Gastroenterology, Academic Department of Internal Medicine, University of Palermo, Palermo, Italy

Publication History

  1. Published Online: 22 JUL 2010
  2. Published Print: 10 SEP 2010

ISBN Information

Print ISBN: 9781405181938

Online ISBN: 9781444314403



  • Evaluation of available evidence;
  • Hepatitis B : Prognosis and treatment;
  • hepatocellular carcinoma (HCC);
  • Hepatitis B virus (HBV) infection;
  • Alpha interferon (IFN);
  • randomized clinical trials (RCTs);
  • alanine aminotransferases (ALT);
  • lamivudine (LAM), entecavir (ETV) and telbivudine (LdT), and nucleotide analogs, adefovir dipivoxyl (ADV) and tenofovir


This chapter contains sections titled:

  • Background

  • Evaluation of available evidence

  • Conclusions

  • References